Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rentosertib - InSilico Medicine

Next Previous
Drug Profile

Rentosertib - InSilico Medicine

Alternative Names: INS018-055; INS018_055; ISM001-055; Rentosertib-InSilico Medicine

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InSilico Medicine
  • Class Antifibrotics; Skin disorder therapies; Small molecules
  • Mechanism of Action Germinal centre kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis
  • Research Skin disorders

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for phase-I development in Idiopathic-pulmonary-fibrosis(In volunteers) in New Zealand (PO)
  • 28 Dec 2024 No recent reports of development identified for phase-0 development in Idiopathic-pulmonary-fibrosis(In volunteers) in Australia (IV)
  • 12 Nov 2024 Efficacy, adverse events and pharmacokinetics data from a phase IIa trial in Idiopathic pulmonary fibrosis released by InSilico medicines

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top